The French government has signed an agreement with the pharmaceutical company UPSA to enhance local production of essential medications, including the production of two new drugs from a list provided by the Health Ministry. UPSA will continue producing paracetamol in response to a demand to prevent a controversy like the one surrounding Doliprane. This agreement also seeks to strengthen France’s pharmaceutical industry against potential relocations to the United States amid financial incentives from the U.S. government.

Source